title: Oxygenation in medetomidine-sedated dogs with and without 100% oxygen insufflation.
abstract: Oxygenation status was evaluated in medetomidine-sedated dogs breathing room air (M) or 100 percent oxygen (MO2). Medetomidine (40 microg/kg IV) administration resulted in peripheral vasoconstriction and decreased venous saturation as measured by an increased oxygen extraction ratio in peripheral tissues. Providing 100 percent oxygen insufflation via face mask reduced desaturation by increasing oxygen content but did not prevent vasoconstriction or reduce the oxygen extraction ratio in peripheral tissues. Atipamezole (200 microg/kg IV) reversed medetomidine-induced vasoconstriction and increased oxygen supply to tissues as indicated by a lower tissue oxygen extraction ratio. The authors conclude that 100 percent oxygen insufflation via face mask during medetomidine sedation (40 micrograms/kg [corrected] IV) benefits tissue oxygenation in healthy dogs.
authors: Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Purdue University, West Lafayette, IN 47908, USA.
authors: Jeff C H
authors: JC
authors: Ko
authors: Ann B
authors: AB
authors: Weil
authors: Takashi
authors: T
authors: Kitao
authors: Mark E
authors: ME
authors: Payton
authors: Tomohito
authors: T
authors: Inoue
mesh_terms: D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D000758:Anesthesia / Q000662:veterinary*; D000818:Animals; D001784:Blood Gas Analysis / Q000662:veterinary; D004285:Dogs / Q000502:physiology*; D005260:Female; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000494:pharmacology*; D007262:Infusions, Intravenous / Q000662:veterinary; D008297:Male; D020926:Medetomidine / Q000008:administration & dosage / Q000494:pharmacology*; D010100:Oxygen / Q000097:blood*; D010102:Oxygen Inhalation Therapy / Q000662:veterinary*; D012119:Respiration / Q000187:drug effects; D016896:Treatment Outcome; D014661:Vasoconstriction / Q000187:drug effects
chemical_list: D000316:Adrenergic alpha-Agonists; D006993:Hypnotics and Sedatives; D020926:Medetomidine; D010100:Oxygen